<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231136</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_115</org_study_id>
    <nct_id>NCT04231136</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacodynamics after single oral dosing of tegoprazan,
      EAPA115 and RAPA115 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Criteria

        -  Pharmacodynamic assessments with intragastric pH

        -  Safety assessments with adverse event monitoring including subjective/objective
           symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 4 over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 6 over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Median pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Mean pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Baseline pH and changes in pH after the administration of investigational products (change of duration %, change of mean pH, change of median pH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 4 during nocturnal period* (*12 hours after administration of investigational product)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 6 during nocturnal period* (*12 hours after administration of investigational product)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Tegoprazan 50 mg tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EAPA115</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of EAPA115 once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAPA115</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of RAPA115 once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EAPA115</intervention_name>
    <description>EAPA115</description>
    <arm_group_label>EAPA115</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAPA115</intervention_name>
    <description>RAPA115</description>
    <arm_group_label>RAPA115</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 19 to 65 years (not inclusive) at the time of signing the informed
             consent form (ICF).

          -  Body mass index (BMI) ≥ 17.5 and &lt; 30.5 kg/m^2 with a body weight ≥ 45 kg at
             screening. Body mass index (kg/m^2) = weight (kg)/height (m)^2

          -  Confirmed as H. pylori negative

          -  A subject without any congenital or chronic disease within 3 years, and has no medical
             examination result as pathological symptoms or signs.

          -  A subject determined eligible for this study based on the screening test such as
             clinical laboratory tests (hematology test, chemistry test, urine test, virus/bacteria
             test, etc.), vital signs, and electrocardiogram.

          -  A subject who is fully informed of the purpose and content of the study and agrees to
             participate in the study on its own will and signs the consent form approved by the
             Institutional Review Board (IRB) of the Seoul National University Hospital, prior to
             participate in the study.

          -  A subject who has the ability and willingness to participate throughout the whole
             study period.

        Exclusion Criteria:

          -  A subject with clinically significant blood, renal, endocrine, respiratory,
             gastrointestinal, urinary, cardiovascular, hepatic, psychical, neurologic, or
             immunologic diseases (except for simple dental past history such as tartar, impacted
             tooth, or wisdom tooth) or evidence.

          -  A subject with a history of gastrointestinal disorders (esophageal diseases such as
             esophageal achalasia or esophageal stricture, Crohn's disease) or surgery (except for
             simple appendectomy, herniotomy, and tooth extraction surgery) that may affect the
             absorption of drugs.

          -  A subject with the *17 allele of CYP2C19 (Ultrarapid metabolizer).

          -  A subject with AST and ALT levels exceeding 3 times of the upper limit of the
             reference range in the screening test.

          -  A subject with a history of excessive caffeine (&gt; 5 units/day) or regular alcohol
             consumption exceeding 210 g/week within 6 months of screening test. (1 glass of beer
             (5%) (250 mL) = 10 g, 1 shot of soju (20%) (50 mL) = 8 g, 1 glass of wine (12%) (125
             mL) = 12 g)

          -  A subject who participated in other clinical trial or bioequivalence study and
             administered the study medication within 6 months prior to the first administration of
             the investigational product of this study.

          -  A subject with significant alcohol or drug abuse within a year of screening test.

          -  A subject who administered drugs that significantly induce or inhibit drug
             metabolizing enzymes within 30 days prior to the first administration of the
             investigational product of this study.

          -  A subject who smoked cigarettes more than 20 per day within 6 months of screening
             test.

          -  A subject who administered prescribed drug or over-the-counter drug within 10 days
             prior to the first administration of the investigational product of this study.

          -  A subject who has donated whole blood within 2 months or those who donated the
             component blood within 1 month prior to the first administration of the
             investigational product of this study.

          -  A subject who has hypersensitivity to the investigational product of this study,
             benzimidazoles, penicillin and macrolide and its related medical history.

          -  A subject with rare genetic problems such as fructose intolerance, glucose-galactose
             malabsorption, or sucrase-isomaltase deficiency.

          -  Pregnant or nursing women

          -  A subject who cannot use reliable contraception during the entire period of the
             clinical trial (e.g, condom use, intrauterine device, tubal ligation, cervical cap,
             contraceptive diaphragm, etc.).

          -  A subject who is judged by the investigator to be ineligible to participate in the
             test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hukeun Lee, MS</last_name>
    <phone>+82-2-6477-0208</phone>
    <email>hukeun.lee@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyosook Seo</last_name>
    <phone>+82-2-6477-0262</phone>
    <email>hs.seo1@kolmar.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <phone>+82-2-2072-1666</phone>
      <email>ijjang@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Jin Jang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

